Overview
Endometrioma of the left ovary, a specific manifestation of endometriosis, involves the formation of a cystic lesion filled with dark, often described as "chocolate" colored fluid within the ovary. This condition significantly impacts women's reproductive health, often contributing to infertility and chronic pelvic pain. Affecting approximately 17–44% of women diagnosed with endometriosis 1, endometriomas can vary in size and are associated with substantial morbidity, affecting quality of life and work performance. Accurate diagnosis and tailored management are crucial in day-to-day practice to mitigate symptoms and improve patient outcomes 12.Pathophysiology
Endometriomas develop due to the implantation of endometrial tissue into the ovarian stroma, where it responds to hormonal fluctuations similarly to uterine endometrium. This ectopic endometrial tissue forms a cyst lined by endometrial-like epithelium, which undergoes cyclic bleeding during menstruation, leading to hemolysis and the characteristic dark fluid accumulation within the cyst 1. Over time, this process can lead to cyst enlargement and potential adhesion formation, contributing to pelvic pain and infertility. The pathophysiology also involves complex interactions between inflammatory mediators, cytokines, and angiogenic factors that promote lesion growth and persistence 5.Epidemiology
Endometriosis, including endometriomas, predominantly affects women of reproductive age, typically between 25 and 40 years old 1. The condition is more prevalent in women with a history of infertility, dysmenorrhea, or pelvic pain. While global incidence and prevalence rates vary, estimates suggest that endometriosis affects about 10% of women of reproductive age 1. Geographic variations exist, with some studies indicating higher prevalence in certain regions, possibly influenced by environmental and genetic factors. No significant temporal trends have been consistently reported, though awareness and diagnostic capabilities have improved over time, potentially influencing reported prevalence 1.Clinical Presentation
Women with endometriomas often present with a constellation of symptoms including chronic pelvic pain, dysmenorrhea, dyspareunia, and infertility. Pain is typically cyclical and exacerbated around menstruation but can be persistent in larger cysts. Larger endometriomas (greater than 7.0 cm) are more likely associated with severe pain 1. Atypical presentations may include vague abdominal discomfort or symptoms mimicking other gynecological conditions. Red-flag features include sudden onset of severe pain, fever, or signs of infection, which warrant immediate evaluation for complications such as cyst rupture or torsion 13.Diagnosis
The diagnosis of endometriomas involves a combination of clinical assessment, imaging, and sometimes laparoscopy. Key diagnostic criteria include:
Clinical History: Detailed history focusing on menstrual symptoms, pain patterns, and fertility issues.
Physical Examination: Pelvic examination may reveal tenderness or palpable masses.
Imaging:
- Ultrasound: Transvaginal ultrasound is highly sensitive, identifying characteristic "chocolate cysts" with low-level echoes and posterior acoustic enhancement.
- MRI: Offers higher resolution and can differentiate endometriomas from other cystic ovarian lesions.
Laparoscopy: Gold standard for definitive diagnosis and staging, allowing direct visualization and biopsy of lesions.
Differential Diagnosis:
- Ovarian Cysts: Benign or malignant; differentiation often requires imaging characteristics and sometimes histopathology.
- Adenomyosis: Can present with similar symptoms but lacks the cystic component visible on imaging.
- Pelvic Inflammatory Disease (PID): Fever, abnormal vaginal discharge, and tenderness may suggest PID, requiring microbiological evaluation 123.Management
First-Line Management
Medical Therapy:
- Combined Hormonal Contraceptives (CHCs): Effective in reducing pain associated with endometriosis. Commonly used agents include estrogen-progestin combinations.
- Dose and Duration: Typically continuous regimens; specific dosing varies but often includes formulations like norethisterone acetate 5 mg daily or similar 4.
- Monitoring: Pain scores, menstrual regularity, and side effects (e.g., breakthrough bleeding, mood changes).
- Gonadotropin-Releasing Hormone (GnRH) Agonists: For refractory pain.
- Dose and Duration: Leuprolide 1 mg monthly or equivalent; duration varies based on response, often 6 months 4.
- Monitoring: Bone density, hot flushes, and other menopausal symptoms.Second-Line Management
Surgical Interventions:
- Laparoscopic Cystectomy: Removal of the endometrioma while preserving the ovary.
- Indications: Large cysts, suspected rupture risk, or failure of medical management.
- Complications: Risk of ovarian reserve loss, adhesions, and recurrence.
- Sclerotherapy: Ethanol or sclerosing agents instilled into the cyst.
- Procedure: Transvaginal or laparoscopic approach.
- Duration and Monitoring: Ethanol instillation for ≥10 minutes; monitor for recurrence and complications like infection 6.Refractory Cases / Specialist Referral
Advanced Surgical Techniques:
- Robot-Assisted Surgery: For complex cases requiring precise dissection and preservation of ovarian function.
- Indications: Severe endometriosis, multiple endometriomas, or prior surgical scarring.
- Outcomes: Reduced blood loss, shorter hospital stays, but requires specialized training and equipment 3.
Conservative Management: Focus on symptom control and quality of life improvement.
- Alternative Therapies: Acupuncture, physical therapy, and pain management strategies.
- Referral: To pain specialists or reproductive endocrinologists for comprehensive care.Complications
Recurrent Cysts: Common following sclerotherapy, especially with shorter instillation times (≤10 minutes) 6.
Ovarian Reserve Loss: Potential risk with surgical interventions, particularly cystectomy.
Adhesions: Can lead to bowel obstruction or pelvic pain; managed with surgical lysis if symptomatic.
Infection: Risk post-sclerotherapy or cyst rupture; requires prompt antibiotic therapy.
Referral Triggers: Persistent pain, suspicion of malignancy, or complications necessitating multidisciplinary care.Prognosis & Follow-Up
The prognosis for women with endometriomas varies widely depending on the size of the cyst, presence of adhesions, and response to treatment. Recurrence rates post-sclerotherapy are notably higher with shorter instillation times (≤10 minutes) compared to longer durations (≥10 minutes) 6. Regular follow-up is essential, typically including:
Clinical Assessments: Every 6-12 months initially, then annually if stable.
Imaging: Ultrasound or MRI every 1-2 years to monitor cyst size and recurrence.
Pain Monitoring: Regular assessment of pain scores and quality of life indicators.Special Populations
Pregnancy: Women planning pregnancy should consider the impact of endometriomas on fertility and discuss surgical options like cystectomy before conception 3.
Pediatrics: Rare but requires careful management due to potential impact on future fertility; conservative approaches are preferred initially 1.
Elderly Women: Focus shifts towards symptom management with medical therapy, as surgical risks increase with age 1.
Comorbidities: Women with coexisting conditions like autoimmune disorders may require tailored treatment plans considering drug interactions and overall health status 1.Key Recommendations
Diagnose Endometriomas Using Transvaginal Ultrasound and Consider Laparoscopy for Confirmation (Evidence: Strong 13).
Initiate Medical Management with Combined Hormonal Contraceptives for Pain Control (Evidence: Moderate 4).
Consider GnRH Agonists for Refractory Pain (Evidence: Moderate 4).
Perform Laparoscopic Cystectomy for Large or Symptomatic Cysts (Evidence: Moderate 3).
Use Ethanol Sclerotherapy for Smaller Cysts, Ensuring ≥10 Minutes of Instillation Time (Evidence: Moderate 6).
Refer Complex Cases to Specialists for Advanced Surgical Techniques (Evidence: Expert opinion 3).
Regular Follow-Up Including Clinical Assessments and Imaging to Monitor Recurrence (Evidence: Moderate 6).
Evaluate and Manage Potential Complications Such as Adhesions and Ovarian Reserve Loss (Evidence: Moderate 36).
Consider Individualized Treatment Plans for Special Populations Like Pregnant Women or Those with Comorbidities (Evidence: Expert opinion 1).
Monitor for Signs of Infection Post-Sclerotherapy or Surgery and Manage Promptly (Evidence: Moderate 6).References
1 Komatsu H, Sunada H, Endo Y, Noma H, Taniguchi F, Harada T. Evaluation of the Characteristics of Ovarian Endometriomas in Patients with Endometriosis: Efficacy of a Low-Dose Estrogen/Progestogen Combination. Gynecologic and obstetric investigation 2023. link
2 Kim GH, Kim PH, Shin JH, Nam IC, Chu HH, Ko HK. Ultrasound-guided sclerotherapy for the treatment of ovarian endometrioma: an updated systematic review and meta-analysis. European radiology 2022. link
3 Zhang Y, Delgado S, Liu J, Guan Z, Guan X. Robot-assisted Transvaginal Natural Orifice Transluminal Endoscopic Surgery for Management of Endometriosis: A Pilot Study of 33 Cases. Journal of minimally invasive gynecology 2021. link
4 Jensen JT, Schlaff W, Gordon K. Use of combined hormonal contraceptives for the treatment of endometriosis-related pain: a systematic review of the evidence. Fertility and sterility 2018. link
5 Rudzitis-Auth J, Menger MD, Laschke MW. Resveratrol is a potent inhibitor of vascularization and cell proliferation in experimental endometriosis. Human reproduction (Oxford, England) 2013. link
6 Noma J, Yoshida N. Efficacy of ethanol sclerotherapy for ovarian endometriomas. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics 2001. link00307-6)
7 Johnston WI. Dydrogesterone and endometriosis. British journal of obstetrics and gynaecology 1976. link